Amini AP, Kirkpatrick JD, Wang CS, et al. Multiscale profiling of protease activity in cancer. Nat Commun. 2022;13(1):5745. doi:10.1038/s41467-022-32988-5.

Layer JV, Cleary P, Brown AJ, et al. Parp3 promotes long-range end joining in murine cells. Proc Natl Acad Sci U S A. 2018;115(40):10076-10081. doi:10.1073/pnas.1801591115.

Schreiber SL, Bernstein BE. Signaling network model of chromatin. Cell. 2002;111(6):771-8.

Yang J, Symes K, Mercola M, Schreiber SL. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol. 1998;8(1):11-8.

Wilson FH, Johannessen CM, Piccioni F, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015;27(3):397-408. doi:10.1016/j.ccell.2015.02.005.

Sharifnia T, Rusu V, Piccioni F, et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014;111(52):18661-6. doi:10.1073/pnas.1412228112.

Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210. doi:10.1007/s00401-018-1879-y.

George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-8. doi:10.1038/nature07397.

Bellmunt J, Selvarajah S, Rodig S, et al. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014;9(8):e103325. doi:10.1371/journal.pone.0103325.

Suvà ML. Genetics and epigenetics of gliomas. Swiss Med Wkly. 2014;144:w14018. doi:10.4414/smw.2014.14018.